EYLEA® is the EURETINA guidelines DME drug of choice in patients with baseline BCVA <69 letters1,a

Superior to ranibizumab in Year 12 in patients with baseline BCVA <69 letters1

EURETINA Guidelines: Mean change in VA over time (aflibercept, ranibizumab, bevacizumab)


“Aflibercept has shown clear superiority to laser therapy in visual and anatomical outcomes. It can be used equivalent [to other anti-VEGFs] for improving vision in eyes with a baseline BCVA letter score of 69 or more. Aflibercept is the drug of choice in DME eyes with baseline BCVA below 69 letters, as it shows superiority to ranibizumab in the first year of treatment.1

“HbA1c levels do not correspond tightly to anti-VEGF treatment effects in the eye, and neither the absolute benefit nor the prognosis is associated with HbA1c levels.1"

a These EURETINA Guidelines included data from Protocol T where the dose of ranibizumab tested was 0.3 mg (US-approved dosage), while the ex-US dosage of ranibizumab is 0.5 mg. The treatment regimen tested in Protocol T was not the label regimen for either EYLEA or ranibizumab.
b P=0.21 vs bevacizumab.

BCVA, best-corrected visual acuity; DME, diabetic macular edema; HbA1c, hemoglobin A1c; VA, visual acuity.


  1. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222.
  2. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.